JP2014531456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531456A5 JP2014531456A5 JP2014532068A JP2014532068A JP2014531456A5 JP 2014531456 A5 JP2014531456 A5 JP 2014531456A5 JP 2014532068 A JP2014532068 A JP 2014532068A JP 2014532068 A JP2014532068 A JP 2014532068A JP 2014531456 A5 JP2014531456 A5 JP 2014531456A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- poly
- composition according
- docetaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000002105 nanoparticle Substances 0.000 claims 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 6
- 229960003668 docetaxel Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 206010070308 Refractory cancer Diseases 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 4
- -1 (lactic acid) -poly (ethylene) Chemical class 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 229920000359 diblock copolymer Polymers 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229920002959 polymer blend Polymers 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229920000547 conjugated polymer Polymers 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161537980P | 2011-09-22 | 2011-09-22 | |
| US61/537,980 | 2011-09-22 | ||
| PCT/US2012/056891 WO2013044219A1 (en) | 2011-09-22 | 2012-09-24 | Methods of treating cancers with therapeutic nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014531456A JP2014531456A (ja) | 2014-11-27 |
| JP2014531456A5 true JP2014531456A5 (https=) | 2015-11-12 |
Family
ID=47049354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532068A Pending JP2014531456A (ja) | 2011-09-22 | 2012-09-24 | 治療用ナノ粒子と癌を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150017245A1 (https=) |
| EP (1) | EP2747761A1 (https=) |
| JP (1) | JP2014531456A (https=) |
| WO (1) | WO2013044219A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
| WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
| US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
| ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| MX356097B (es) | 2012-09-17 | 2018-05-14 | Pfizer Inc Star | Proceso para la preparacion de nanoparticulas terapeuticas. |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| KR20160024985A (ko) * | 2013-06-28 | 2016-03-07 | 바인드 쎄라퓨틱스, 인크. | 암 치료를 위한 도세탁셀 중합체성 나노입자 |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| ES2640648T3 (es) | 2013-09-16 | 2017-11-03 | Astrazeneca Ab | Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| MA39734B1 (fr) | 2014-03-14 | 2019-07-31 | Pfizer | Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation |
| WO2015142605A2 (en) * | 2014-03-17 | 2015-09-24 | Merck Sharp & Dohme Corp. | Polymeric nanoparticles and methods of making and using same |
| CA2946149A1 (en) * | 2014-04-18 | 2015-10-22 | Pfizer Inc. | Methods of treating cancers with therapeutic nanoparticles |
| CA2946155A1 (en) * | 2014-04-18 | 2015-10-22 | Pfizer Inc. | Nanoparticles comprising docetaxel for treating cancers having a k-ras mutation |
| WO2016008401A1 (zh) * | 2014-07-15 | 2016-01-21 | 腾鑫 | 一种含多西他赛的药物组合物 |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
| EP3307242A4 (en) | 2015-06-09 | 2019-01-23 | Sun Pharma Advanced Research Company Limited | PICn-01 |
| WO2017070620A2 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| AU2016342049B2 (en) | 2015-10-22 | 2023-05-18 | Modernatx, Inc. | Herpes simplex virus vaccine |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| MX2018004917A (es) | 2015-10-22 | 2019-04-01 | Modernatx Inc | Vacuna de virus sincitial respiratorio. |
| CA3002912A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| RS63135B1 (sr) | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| KR20200018634A (ko) * | 2017-06-28 | 2020-02-19 | 가부시키가이샤 센탄이료카이하츠 | 의약조성물 및 종양면역활성 촉진제 |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776100T3 (es) * | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
| EP2136788B1 (en) * | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
| JP2012501965A (ja) * | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| ES2721850T3 (es) * | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
| JP2010106019A (ja) * | 2008-10-02 | 2010-05-13 | Kanazawa Univ | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 |
| US8357401B2 (en) * | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
| JP6175237B2 (ja) * | 2009-12-15 | 2017-08-02 | ファイザー・インク | コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法 |
| ES2780156T3 (es) * | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| WO2011079279A2 (en) * | 2009-12-23 | 2011-06-30 | Board Of Trustees Of The University Of Illinois | Nanoconjugates and nanoconjugate formulations |
-
2012
- 2012-09-24 EP EP12775568.4A patent/EP2747761A1/en not_active Withdrawn
- 2012-09-24 WO PCT/US2012/056891 patent/WO2013044219A1/en not_active Ceased
- 2012-09-24 US US14/346,456 patent/US20150017245A1/en not_active Abandoned
- 2012-09-24 JP JP2014532068A patent/JP2014531456A/ja active Pending
-
2017
- 2017-05-23 US US15/603,151 patent/US20170266293A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531456A5 (https=) | ||
| JP2019512006A5 (https=) | ||
| Lee et al. | PLA micro-and nano-particles | |
| HRP20200407T1 (hr) | Terapeutske polimerne nanočestice i postupci dobivanja i korištenja istih | |
| Mura et al. | Lipid prodrug nanocarriers in cancer therapy | |
| Cheng et al. | Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery | |
| Gad et al. | Targeting cancer using polymeric nanoparticle mediated combination chemotherapy | |
| Yu et al. | Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) complex nanoparticles for tumor therapy | |
| Tamboli et al. | Novel pentablock copolymer (PLA–PCL–PEG–PCL–PLA)-based nanoparticles for controlled drug delivery: effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles | |
| Qu et al. | One‐Pot Synthesis of pH‐Responsive Eudragit‐Mesoporous Silica Nanocomposites Enable Colonic Delivery of Glucocorticoids for the Treatment of Inflammatory Bowel Disease | |
| JP2010509331A5 (https=) | ||
| Xu et al. | The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells | |
| ES2737692T3 (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas | |
| Aguilar et al. | On-demand drug release and hyperthermia therapy applications of thermoresponsive poly-(NIPAAm-co-HMAAm)/polyurethane core-shell nanofiber mat on non-vascular nitinol stents | |
| JP2010512384A5 (https=) | ||
| JP2013503174A5 (https=) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| JP2012522055A5 (https=) | ||
| JP2014240439A5 (https=) | ||
| EA201170039A1 (ru) | Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения | |
| Colby et al. | Nanoparticle drug‐delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle | |
| JP2015134825A5 (https=) | ||
| WO2010091187A3 (en) | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof | |
| JP2015519330A5 (https=) | ||
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma |